Cargando…
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity agains...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732767/ https://www.ncbi.nlm.nih.gov/pubmed/29262601 http://dx.doi.org/10.18632/oncotarget.21951 |